US › Healthcare

AC Immune Ltd (ACIU)

US · Healthcare · Biotechnology

$2.23+5.69%

Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Revenue

$3.2M

Revenue YoY

+245.5%

Net profit

$-8.8M

EPS

$-0.16

EPS estimate

$-0.22

Net margin

-269.7%

EPS came in at -0.16 against a street estimate of -0.22 — a beat of 27.3%.

Key statistics

Market cap

$209.8M

Forward P/E

12.3

P/B

6.35

Book value

$0.54

EPS (TTM)

$-0.44

52-week high

$3.90

52-week low

$2.02

50-day MA

$2.55

200-day MA

$2.70

Beta

1.61

Analyst view

Analysts rate AC Immune Ltd a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $8.69.

Shareholding

Insiders

38.09%

Institutions

24.34%

Largest institutional holders

Fund	Stake
Bvf Inc	19.94%
Wells Fargo & Co	1.01%
Renaissance Technologies Corp	0.84%
Millennium Management LLC	0.78%
BlackRock Inc	0.52%
Dimensional Fund Advisors, Inc.	0.34%
Arrowstreet Capital Limited Partnership	0.23%
Citadel Advisors Llc	0.21%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for AC Immune Ltd — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.